Discovery of a Novel, Orally Active Himbacine-Based Thrombin Receptor Antagonist (SCH 530348) with Potent Antiplatelet Activity
- 1 May 2008
- journal article
- research article
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 51 (11) , 3061-3064
Abstract
The discovery of an exceptionally potent series of thrombin receptor (PAR-1) antagonists based on the natural product himbacine is described. Optimization of this series has led to the discovery of 4 (SCH 530348), a potent, oral antiplatelet agent that is currently undergoing Phase-III clinical trials for acute coronary syndrome (unstable angina/non-ST segment elevation myocardial infarction) and secondary prevention of cardiovascular events in high-risk patients.Keywords
This publication has 29 references indexed in Scilit:
- Antithrombotic TherapyCurrent Molecular Medicine, 2006
- The Molecular and Cellular Basis of Atherosclerosis and Plaque RuptureCurrent Cardiology Reviews, 2005
- Pathophysiology of Coronary Artery DiseaseCirculation, 2005
- Inflammation, Atherosclerosis, and Coronary Artery DiseaseNew England Journal of Medicine, 2005
- Macrophage Activation in Atherosclerosis: Pathogenesis and Pharmacology of Plaque RuptureCurrent Vascular Pharmacology, 2005
- Rapamycin for Cardiac Transplant Rejection and VasculopathyCirculation, 2003
- New AnticoagulantsAmerican Journal of Cardiovascular Drugs, 2003
- Classic Q wave myocardial infarctionPostgraduate Medicine, 2002
- Unstable Angina PectorisNew England Journal of Medicine, 2000
- Non-Q wave myocardial infarctionPostgraduate Medicine, 2000